Skip to main content
main-content

Zeitschrift

Cancer Chemotherapy and Pharmacology

Cancer Chemotherapy and Pharmacology 6/2014

Ausgabe 6/2014

Inhaltsverzeichnis ( 23 Artikel )

01.06.2014 | Review Article | Ausgabe 6/2014

Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with renal cell carcinoma

Xavier García del Muro, Enrique Gallardo, Iciar García Carbonero, Nuria Laínez, María José Méndez, Pablo Maroto, María Ochoa de Olza, Javier Puente, Gaspar Reynes, José Rubio, Carmen Santander, Cristina Suárez, Sergio Vázquez Estévez, Daniel Castellano

01.06.2014 | Original Article | Ausgabe 6/2014

Effect of lenvatinib (E7080) on the QTc interval: results from a thorough QT study in healthy volunteers

Robert C. Shumaker, Meijian Zhou, Min Ren, Jean Fan, Gresel Martinez, Jagadeesh Aluri, Borje Darpo

01.06.2014 | Original Article | Ausgabe 6/2014 Open Access

An evaluation of the potential for drug–drug interactions between bendamustine and rituximab in indolent non-Hodgkin lymphoma and mantle cell lymphoma

Mona Darwish, John M. Burke, Edward Hellriegel, Philmore Robertson Jr., Luann Phillips, Elizabeth Ludwig, Mihaela C. Munteanu, Mary Bond

01.06.2014 | Original Article | Ausgabe 6/2014

Addition of aprepitant improves protection against cisplatin-induced emesis when a conventional anti-emetic regimen fails

Weiheng Hu, Jian Fang, Jun Nie, Ling Dai, Xiaoling Chen, Jie Zhang, Xiangjuan Ma, Guangming Tian, Jindi Han

01.06.2014 | Original Article | Ausgabe 6/2014

Mouse pharmacokinetics and metabolism of the curcumin analog, 4-piperidinone,3,5-bis[(2-fluorophenyl)methylene]-acetate(3E,5E) (EF-24; NSC 716993)

Joel M. Reid, Sarah A. Buhrow, Judith A. Gilbert, Lee Jia, Mamoru Shoji, James P. Snyder, Matthew M. Ames

01.06.2014 | Original Article | Ausgabe 6/2014

Treatment results and prognostic factors for advanced squamous cell carcinoma of the hypopharynx treated with concurrent chemoradiotherapy

Takahide Taguchi, Goshi Nishimura, Masahiro Takahashi, Masanori Komatsu, Daisuke Sano, Naoko Sakuma, Ken-ichiro Yabuki, Yasuhiro Arai, Hideaki Takahashi, Masaharu Hata, Izumi Koike, Nobuhiko Oridate

01.06.2014 | Original Article | Ausgabe 6/2014 Open Access

A phase II trial of Xeloda and oxaliplatin (XELOX) neo-adjuvant chemotherapy followed by surgery for advanced gastric cancer patients with para-aortic lymph node metastasis

Yan Wang, Yi-yi Yu, Wei Li, Yi Feng, Jun Hou, Yuan Ji, Yi-hong Sun, Kun-tang Shen, Zhen-bin Shen, Xin-yu Qin, Tian-shu Liu

01.06.2014 | Original Article | Ausgabe 6/2014

Serum levels of LDH, CEA, and CA19-9 have prognostic roles on survival in patients with metastatic pancreatic cancer receiving gemcitabine-based chemotherapy

Faruk Tas, Senem Karabulut, Rumeysa Ciftci, Fatma Sen, Burak Sakar, Rian Disci, Derya Duranyildiz

01.06.2014 | Original Article | Ausgabe 6/2014

Phase I and pharmacokinetic study of polymeric micelle-formulated paclitaxel in adult Chinese patients with advanced solid tumors

Fangfang Lv, Junning Cao, Jian Zhang, Jun Qian, Wei Peng, Si Sun, Wenhua Li, Wen Zhang, Weijian Guo, Jin Li

01.06.2014 | Original Article | Ausgabe 6/2014

Impact of variable CYP genotypes on breast cancer relapse in patients undergoing adjuvant tamoxifen therapy

Jessica Mwinyi, Kerstin Vokinger, Alexander Jetter, Urs Breitenstein, Christian Hiller, Gerd A. Kullak-Ublick, Andreas Trojan

01.06.2014 | Original Article | Ausgabe 6/2014

Pharmacokinetics of pazopanib administered in combination with bevacizumab

Diane-Charlotte Imbs, Sylvie Négrier, Philippe Cassier, Antoine Hollebecque, Andrea Varga, Ellen Blanc, Thierry Lafont, Bernard Escudier, Jean-Charles Soria, David Pérol, Etienne Chatelut

01.06.2014 | Original Article | Ausgabe 6/2014

Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients

Katherine M. Slusarz, Vanessa L. Merker, Alona Muzikansky, Sanjeev A. Francis, Scott R. Plotkin

01.06.2014 | Original Article | Ausgabe 6/2014

Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737) in combination with docetaxel in patients with advanced solid tumors

Ramon Salazar, Serafin Morales, Marta Gil-Martín, Elena Aguirre, Ana Oaknin, Margarita Garcia, Sophie Callies, Enaksha R. Wickremsinhe, Karim A. Benhadji, Antonio Llombart

01.06.2014 | Original Article | Ausgabe 6/2014

Safety and efficacy of gemcitabine or pemetrexed in combination with a platinum in patients with non-small-cell lung cancer and prior interstitial lung disease

Moon Ki Choi, Jung Yong Hong, Wonjin Chang, Moonjin Kim, Sungmin Kim, Hyun Ae Jung, Su Jin Lee, Silvia Park, Man Pyo Chung, Jong-Mu Sun, Keunchil Park, Myung-Ju Ahn, Jin Seok Ahn

01.06.2014 | Original Article | Ausgabe 6/2014

An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck

Vassiliki Saloura, Ezra E. W. Cohen, Lisa Licitra, Salem Billan, Jose Dinis, Steen Lisby, Thomas C. Gauler

01.06.2014 | Original Article | Ausgabe 6/2014

An open-label study to investigate the cardiac safety profile of cabazitaxel in patients with advanced solid tumors

Pierre Maison-Blanche, Shaker Dakhil, Ari Baron, Sylvie Rottey, Fred Millard, Gedske Daugaard, Jean-Pascal Machiels, William Conkright, Sunil Sharma, Patricia M. M. B. Soetekouw, Jeffrey Yachnin, Lisa Sengeløv, Peter Van Veldhuizen, Sanjiv S. Agarwala, Dorothée Sémiond, Mustapha Chadjaa, Liji Shen, James L. Wade

01.06.2014 | Original Article | Ausgabe 6/2014 Open Access

Safety analysis of two different regimens of uracil–tegafur plus leucovorin as adjuvant chemotherapy for high-risk stage II and III colon cancer in a phase III trial comparing 6 with 18 months of treatment: JFMC33-0502 trial

Takashi Tsuchiya, Sotaro Sadahiro, Kazuaki Sasaki, Ken Kondo, Kenji Katsumata, Genichi Nishimura, Yoshihiro Kakeji, Hideo Baba, Takayuki Morita, Keiji Koda, Seiji Sato, Junji Matsuoka, Yoshiyuki Yamaguchi, Hisashi Usuki, Chikuma Hamada, Susumu Kodaira, Shigetoyo Saji

01.06.2014 | Original Article | Ausgabe 6/2014

Effects of a novel proteasome inhibitor BU-32 on multiple myeloma cells

Sudipa S. Roy, Nameer B. Kirma, Bindu Santhamma, Rajeshwar R. Tekmal, Joseph K. Agyin

01.06.2014 | Original Article | Ausgabe 6/2014

The novel thymidylate synthase inhibitor trifluorothymidine (TFT) and TRAIL synergistically eradicate non-small cell lung cancer cells

Kaamar Azijli, Ingrid A. M. van Roosmalen, Jorn Smit, Saravanan Pillai, Masakazu Fukushima, Steven de Jong, Godefridus J. Peters, Irene V. Bijnsdorp, Frank A. E. Kruyt

01.06.2014 | Original Article | Ausgabe 6/2014

Pharmacokinetics and exposure–effect relationships of capecitabine in elderly patients with breast or colorectal cancer

Z. Daher Abdi, S. Lavau-Denes, A. Prémaud, S. Urien, F. L. Sauvage, J. Martin, S. Leobon, P. Marquet, N. Tubiana-Mathieu, A. Rousseau

01.06.2014 | Clinical Trial Report | Ausgabe 6/2014 Open Access

Phase I study of adjuvant chemotherapy with gemcitabine plus cisplatin in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1004)

Masanori Toyoda, Tetsuo Ajiki, Yutaka Fujiwara, Hiroaki Nagano, Shogo Kobayashi, Daisuke Sakai, Etsuro Hatano, Masashi Kanai, Shoji Nakamori, Atsushi Miyamoto, Akihito Tsuji, Satoshi Kaihara, Hisashi Ikoma, Shigekazu Takemura, Hideyoshi Toyokawa, Hiroaki Terajima, Satoshi Morita, Tatsuya Ioka

01.06.2014 | Short Communication | Ausgabe 6/2014

Pharmacokinetics and safety of cetuximab in a patient with renal dysfunction

L. L. Krens, J. M. Baas, M. C. Verboom, G. Paintaud, C. Desvignes, H. J. Guchelaar, H. Gelderblom

01.06.2014 | Short Communication | Ausgabe 6/2014

Successful challenges using native E. coli asparaginase after hypersensitivity reactions to PEGylated E. coli asparaginase

C. A. Fernandez, E. Stewart, J. C. Panetta, M. R. Wilkinson, A. R. Morrison, F. D. Finkelman, J. T. Sandlund, C. H. Pui, S. Jeha, M. V. Relling, P. K. Campbell

Aktuelle Ausgaben


 

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise